ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ETX E-therapeutics Plc

11.00
-0.15 (-1.35%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
E-therapeutics Plc LSE:ETX London Ordinary Share GB00B2823H99 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -1.35% 11.00 10.50 10.80 11.30 10.95 11.30 169,640 16:29:55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 475k -8.27M -0.0142 -7.75 64.22M

e-Therapeutics plc Directors' Dealings and Issue of Equity (8817L)

06/10/2016 10:12am

UK Regulatory


E-therapeutics (LSE:ETX)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more E-therapeutics Charts.

TIDMETX

RNS Number : 8817L

e-Therapeutics plc

06 October 2016

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Directors' Dealings and Issue of Equity

Oxford and Newcastle, UK, 6 October 2016 - e-Therapeutics plc (AIM: ETX) the drug discovery company, announces that on 5 October 2016 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 41,204 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at an average price of 11.327 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones Non-Executive Director fees net of tax paid during the period from 1 May 2016 to 30 September 2016.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 12 October 2016. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, Professor Jones will be interested in a total of 70,580 ordinary shares of 0.1p in the Company, representing approximately 0.03% of the Company's issued share capital.

Following Admission the total number of ordinary shares in the Company with voting rights in issue will be 268,389,125. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The Company also announces today that on 5 October 2016 Professor Jones entered into a binding contractual arrangement with the Company under which he agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-Therapeutics' ordinary shares.

The new shares will be issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid will be the average of the closing mid-market price for the five business days prior to the date of issue. The terms pursuant to which Professor Jones will purchase the shares are fixed and he has irrevocably committed to such terms.

 
   1     Details of the person discharging 
           managerial responsibilities/person 
           closely associated 
   ----  ------------------------------------------------ 
    a)    Name                  Trevor Jones 
   ----  --------------------  -------------------------- 
    2     Reason for the notification 
   ----  ------------------------------------------------ 
    a)    Position/status       Director 
   ----  --------------------  -------------------------- 
    b)    Initial               Initial Notification 
           notification 
           /Amendment 
   ----  --------------------  -------------------------- 
    3     Details of the issuer, emission allowance 
           market participant, auction platform, 
           auctioneer or auction monitor 
   ----  ------------------------------------------------ 
    a)    Name                  e-Therapeutics plc 
   ----  --------------------  -------------------------- 
    b)    Legal Entity          N/A 
           Identifier 
   ----  --------------------  -------------------------- 
    4     Details of the transaction(s): section 
           to be repeated for (i) each type 
           of instrument; (ii) each type of 
           transaction; (iii) each date; and 
           (iv) each place where transactions 
           have been conducted 
   ----  ------------------------------------------------ 
    a)    Description           Ordinary shares of 0.1 
           of the financial      pence each 
           instrument, 
           type of 
           instrument 
 
           Identification        GB00B2823H99 
           code 
   ----  --------------------  -------------------------- 
    b)    Nature of             Purchase of new shares 
           the transaction 
   ----  --------------------  -------------------------- 
    c)    Currency              GBP 
   ----  --------------------  -------------------------- 
    d)    Price(s)              Price(s)        Volume(s) 
           and volume(s) 
   ----  --------------------  --------------  ---------- 
      11.327 pence                              41,204 
     ----------------------------------------  ---------- 
 
    e)    Aggregated 
           information 
           - Aggregated          41,204 
           volume 
           - Price               11.327 pence 
           - Aggregated          GBP4,667.12 
           total 
   ----  --------------------  -------------------------- 
    f)    Date of               5 October 2016 
           the transaction 
   ----  --------------------  -------------------------- 
    g)    Place of              London Stock Exchange 
           the transaction 
   ----  --------------------  -------------------------- 
 
 

-Ends-

Contacts:

 
 e-Therapeutics plc                   Tel: +44 (0) 1993 
  Iain Ross, Chairman                  883 125 
  Steve Medlicott, Finance Director    www.etherapeutics.co.uk 
 Numis Securities Limited             Tel: +44 (0) 207 260 
  Michael Meade / Freddie Barnfield    1000 
  (Corporate Finance)                  www.numis.com 
  James Black (Corporate Broking) 
 Instinctif Partners                  Tel: +44 (0) 207 457 
  Melanie Toyne Sewell / Jayne         2020 
  Crook / Emma Barlow                  Email: e-therapeutics@instinctif.com 
 

About e-Therapeutics plc

e-Therapeutics (AIM: ETX) is a drug discovery company with a proprietary discovery platform based on advances in network pharmacology and chemical biology. The Company is applying its platform to the discovery of new drug candidates. The therapeutic focus of the Company's activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and anti-infectives. The platform is highly productive, yielding multiple potent and selective molecules at a much higher rate and more quickly than is reported for conventional drug discovery.

e-Therapeutics has a variety of preclinical stage assets, including ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway inhibition and ETS5200, broad spectrum antivirals. The Company has recently completed a phase IIb clinical trial for ETS6103, a drug to treat major depressive disorder.

The Company is fully funded to advance its drug discovery programmes. It is based in Oxford and Newcastle, UK. For more information, visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHMMMGGLVGGVZG

(END) Dow Jones Newswires

October 06, 2016 05:12 ET (09:12 GMT)

1 Year E-therapeutics Chart

1 Year E-therapeutics Chart

1 Month E-therapeutics Chart

1 Month E-therapeutics Chart

Your Recent History

Delayed Upgrade Clock